Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab, and Immunoembolization in Metastatic Uveal Melanoma
NCT03472586Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2018
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, nivolumab in Uveal melanoma (UM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT03472586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472586.